RWAY:NASDAQRunway Growth Finance Corp. Analysis
Data as of 2026-04-29 - not real-time
$6.60
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Runway Growth Finance Corp. (RWAY) is trading at $6.60, which sits below its 20‑day SMA of $6.65 and 50‑day SMA of $7.18, signaling a short‑term bearish bias. The RSI of 43.5 and a modestly bullish MACD histogram suggest limited upside momentum, while decreasing volume and a 30‑day volatility of 35.7% point to heightened price instability. Valuation metrics appear attractive – a trailing P/E of 7.1 versus an industry average of 17.5 and a P/B of 0.49 – yet the DCF fair value of $1.30 implies the market may be overpaying, and a dividend yield of 20.8% is unsustainable given a payout ratio above 150%. The company’s revenue is contracting (-11% YoY) and its leverage is high, with a debt‑to‑equity of 92.8, adding to financial risk.
The upcoming Q1 2026 results and recent acquisition of SWK Holdings, which expands exposure to healthcare and life‑sciences, could provide a catalyst for a modest recovery. However, the combination of high volatility, decreasing liquidity, and regulatory pressures on BDCs suggests caution. Investors should weigh the cheap relative multiples against the unsustainable dividend and elevated debt before deciding on positioning.
The upcoming Q1 2026 results and recent acquisition of SWK Holdings, which expands exposure to healthcare and life‑sciences, could provide a catalyst for a modest recovery. However, the combination of high volatility, decreasing liquidity, and regulatory pressures on BDCs suggests caution. Investors should weigh the cheap relative multiples against the unsustainable dividend and elevated debt before deciding on positioning.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below short‑term moving averages
- Decreasing volume and high short‑term volatility
- Unsustainable dividend payout ratio
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential upside to analyst target around $9
- Recent acquisition expanding sector exposure
- Valuation multiples remain attractive relative to peers
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Low price‑to‑earnings and price‑to‑book ratios
- Opportunity to benefit from a turnaround in earnings
- Sector positioning in high‑growth technology and healthcare loans
Key Metrics & Analysis
Financial Health
Revenue Growth-11.10%
Profit Margin24.79%
P/E Ratio7.1
ROE6.81%
ROA6.07%
Debt/Equity92.77
P/B Ratio0.5
Op. Cash Flow$186.3M
Free Cash Flow$36.3M
Industry P/E17.5
Technical Analysis
TrendBearish
RSI43.5
Support$6.36
Resistance$7.07
MA 20$6.65
MA 50$7.18
MA 200$9.20
MACDBullish
VolumeDecreasing
Fear & Greed Index89.59
Valuation
Fair Value$1.31
Target Price$8.89
Upside/Downside34.74%
GradeFair
TypeValue
Dividend Yield20.76%
Risk Assessment
Beta0.70
Volatility35.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.